Clinical Trial Update: Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema [Phase 3]

View source ↗

Summary

Phase 3 trial comparing brolucizumab to aflibercept for diabetic macular edema was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Aflibercept (Aflibercept)
• Brolucizumab (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetic Macula Edema | Phase 3 | Status: WITHDRAWN